Gastrointestinal Cancer Clinical Trials

ANAL
ECOG/ACRIN-EA2182: A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE) The purpose of this study is to compare lower-dose chemoradiation therapy to standard-dose chemoradiation therapy. Learn more about the ECOG/ACRIN-EA2182 trial or call the Reading Hospital Protocol Office at 484-628-8193.

ANAL

ECOG/ACRIN-EA2182: A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)

The purpose of this study is to compare lower-dose chemoradiation therapy to standard-dose chemoradiation therapy.

Learn more about the ECOG/ACRIN-EA2182 trial or call the Reading Hospital Protocol Office at 484-628-8193.

COLON/RECTAL
A022104: The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer. The purpose of this study is to compare the usual treatment alone (FOLFOX or CAPOX after chemoradiation) to using FOLFIRINOX after chemoradiation. Learn more about the A022104/JANUS trial or call the Reading Hospital Protocol Office at 484-628-8193.
S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and IrinotecN (cetiri) IN Advanced/Medtastatic Colorectal Cancer (mCRC) with HER-2-Amplification Pottstown Hospital Active Clinical Trials Learn more about S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.
S2107: Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer. The purpose of this study is to compare the usual treatment (encorafenib and cetuximab) alone to using nivolumab plus the usual treatment. Learn more about the S2107 trial or call the Reading Hospital Protocol Office at 484-628-8193.
NRG-G1008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA). The purpose of this study is to find out if circulating tumor DNA (ctDNA) testing results can be used to determine if the usual approach or mFOLFIRINOX should be used to prevent colon cancer from returning in patients that are ctDNA positive and if the usual approach compared to ctDNA testing every 3 months should be used to prevent colon cancer from returning in patients that are ctDNA negative. Learn more about the NRG-GI008 trial or call the Reading Hospital Protocol Office at 484-628-8193.
NRG-GI004: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer The purpose of this screening step is to perform a genetic test on the colorectal cancer tumor sample to see if it has a HER-2 gene amplification. Learn more about the NRG-GI004 trial or call the Reading Hospital Protocol Office at 484-628-8193.
16-002 / NSABP C-14: CORRECT-MRD II: Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease. The purpose of this research study is to review the ability of the Exact Sciences’ Minimal Residual Disease (Exact MRD) test to detect cancer recurrence after surgery. Learn more about the 16-002 / NSABP C-14 trial or call the Reading Hospital Protocol Office at 484-628-8193.
Biofilm Epidemiology and Mechanisms of Colon Cancer Johns Hopkins Primary Investigator: Cynthia Sears, MD Reading Hospital Primary Investigator: Louis LaLuna, MD This research is being done to learn more about why people get colon cancer. We are looking to identify specific bacteria in the colon that may be linked to the development of colon cancer, and small biopsies will be taken along with other samples to look for these bacteria. This study is closed to enrollment. Learn more about the Biofilm trial. View on Cancer.gov or call the Clinical Trials Office at 484-628-8585 for more information.

COLON/RECTAL

A022104: The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer.

The purpose of this study is to compare the usual treatment alone (FOLFOX or CAPOX after chemoradiation) to using FOLFIRINOX after chemoradiation.

Learn more about the A022104/JANUS trial or call the Reading Hospital Protocol Office at 484-628-8193.

S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and IrinotecN (cetiri) IN Advanced/Medtastatic Colorectal Cancer (mCRC) with HER-2-Amplification Pottstown Hospital Active Clinical Trials

Learn more about S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

S2107: Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer.

The purpose of this study is to compare the usual treatment (encorafenib and cetuximab) alone to using nivolumab plus the usual treatment.

Learn more about the S2107 trial or call the Reading Hospital Protocol Office at 484-628-8193.

NRG-G1008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA).

The purpose of this study is to find out if circulating tumor DNA (ctDNA) testing results can be used to determine if the usual approach or mFOLFIRINOX should be used to prevent colon cancer from returning in patients that are ctDNA positive and if the usual approach compared to ctDNA testing every 3 months should be used to prevent colon cancer from returning in patients that are ctDNA negative.

Learn more about the NRG-GI008 trial or call the Reading Hospital Protocol Office at 484-628-8193.

NRG-GI004: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

The purpose of this screening step is to perform a genetic test on the colorectal cancer tumor sample to see if it has a HER-2 gene amplification.

Learn more about the NRG-GI004 trial or call the Reading Hospital Protocol Office at 484-628-8193.

16-002 / NSABP C-14: CORRECT-MRD II: Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease.

The purpose of this research study is to review the ability of the Exact Sciences’ Minimal Residual Disease (Exact MRD) test to detect cancer recurrence after surgery.

Learn more about the 16-002 / NSABP C-14 trial or call the Reading Hospital Protocol Office at 484-628-8193.

Biofilm Epidemiology and Mechanisms of Colon Cancer

Johns Hopkins Primary Investigator: Cynthia Sears, MD

Reading Hospital Primary Investigator: Louis LaLuna, MD

This research is being done to learn more about why people get colon cancer. We are looking to identify specific bacteria in the colon that may be linked to the development of colon cancer, and small biopsies will be taken along with other samples to look for these bacteria. This study is closed to enrollment.

Learn more about the Biofilm trial.

View on Cancer.gov or call the Clinical Trials Office at 484-628-8585 for more information.

ESOPHAGEAL AND GASTRIC
ECOG/ACRIN-EA2183: A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic Esophageal and Gastric Adenocarcinoma The purpose of this study is to compare the usual treatment, which consists of chemotherapy alone, to chemotherapy plus the addition of radiation. Learn more about the ECOG/ACRIN-EA2183 trial or call the Reading Hospital Protocol Office at 484-628-8193.

ESOPHAGEAL AND GASTRIC

ECOG/ACRIN-EA2183: A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic Esophageal and Gastric Adenocarcinoma

The purpose of this study is to compare the usual treatment, which consists of chemotherapy alone, to chemotherapy plus the addition of radiation.

Learn more about the ECOG/ACRIN-EA2183 trial or call the Reading Hospital Protocol Office at 484-628-8193.

PANCREATIC
TJU-08D.213: Jefferson Pancreas Tumor Registry (JPTR). The purpose of this research study is to collect information to determine if pancreas tumors and related conditions tend to occur more frequently in families with a history of the disease and to determine environmental and occupational risk factors to which patients may be exposed. Learn more about the TJU-08D.213 trial or call the Reading Hospital Protocol Office at 484-628-8193.
Alliance-A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer. The purpose of this study is to compare the usual treatment approach (surgery followed by chemotherapy) to using chemotherapy followed by surgery and then more chemotherapy. Learn more about the Alliance-A021806 trial or call the Reading Hospital Protocol Office at 484-628-8193.

PANCREATIC

TJU-08D.213: Jefferson Pancreas Tumor Registry (JPTR).

The purpose of this research study is to collect information to determine if pancreas tumors and related conditions tend to occur more frequently in families with a history of the disease and to determine environmental and occupational risk factors to which patients may be exposed.

Learn more about the TJU-08D.213 trial or call the Reading Hospital Protocol Office at 484-628-8193.

Alliance-A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer.

The purpose of this study is to compare the usual treatment approach (surgery followed by chemotherapy) to using chemotherapy followed by surgery and then more chemotherapy.

Learn more about the Alliance-A021806 trial or call the Reading Hospital Protocol Office at 484-628-8193.